Solensia for Cats – Monthly Injectable Arthritis Pain Relief
Solensia is a prescription-only injectable treatment designed to help relieve the pain of osteoarthritis (OA) in cats. It is the first and only monoclonal antibody therapy approved for use in cats for this condition. Administered once a month by a veterinary professional or by owners at home with suitable training, Solensia offers a novel approach to managing chronic pain in cats affected by degenerative joint disease.
Solensia contains the active ingredient frunevetmab, a feline-specific monoclonal antibody that targets a protein known as nerve growth factor (NGF). NGF plays a critical role in the transmission of pain signals and the progression of osteoarthritis. By binding to NGF, frunevetmab prevents it from interacting with pain receptors, thereby reducing pain sensitivity and inflammation in affected joints.
VETERINARY PRESCRIPTION REQUIRED
...
Solensia for Cats – Monthly Injectable Arthritis Pain Relief
Solensia is a prescription-only injectable treatment designed to help relieve the pain of osteoarthritis (OA) in cats. It is the first and only monoclonal antibody therapy approved for use in cats for this condition. Administered once a month by a veterinary professional or by owners at home with suitable training, Solensia offers a novel approach to managing chronic pain in cats affected by degenerative joint disease.
Solensia contains the active ingredient frunevetmab, a feline-specific monoclonal antibody that targets a protein known as nerve growth factor (NGF). NGF plays a critical role in the transmission of pain signals and the progression of osteoarthritis. By binding to NGF, frunevetmab prevents it from interacting with pain receptors, thereby reducing pain sensitivity and inflammation in affected joints.
VETERINARY PRESCRIPTION REQUIRED
Unlike traditional pain medications, such as non-steroidal anti-inflammatory drugs (NSAIDs), which act broadly on various pathways, Solensia offers a more targeted approach. Because it is a biologic medication specifically engineered to match feline biology, it is generally well tolerated by most cats. The injection is given subcutaneously, typically by a vet during a monthly appointment.
Cats with osteoarthritis may not always show obvious signs of pain. Common behavioural changes include reduced activity, reluctance to jump, altered grooming habits, and changes in temperament. These symptoms are often misinterpreted as a natural part of ageing, when in fact they can be indicators of chronic joint pain.
Osteoarthritis in cats is a progressive, degenerative disease that affects the cartilage and surrounding tissues of joints. It can occur in cats of any age but is most commonly seen in older animals. The condition causes joint stiffness, inflammation, and pain, often resulting in decreased mobility and a lower quality of life. Cats with Osteoarthritis may also experience muscle loss in the limbs, difficulties with posture, or hesitation to use stairs and elevated surfaces.
Osteoarthritis is frequently underdiagnosed in felines due to their tendency to mask pain and discomfort. Routine veterinary assessments, including orthopaedic examinations and diagnostic imaging, play an important role in early identification. Management of the disease requires a multimodal approach, combining medical treatment with environmental modifications and weight control. Solensia is designed to be part of this long-term management plan, offering consistent monthly relief with a single injection.
One of the primary benefits of Solensia is its ease of administration. Cats are often resistant to oral medication, and daily dosing can be difficult for both pet and owner. The once-monthly injectable format eliminates the need for daily tablets or capsules. Solensia also does not involve the gastrointestinal or renal systems to the extent that some oral pain medications do, making it a suitable option for cats with pre-existing kidney or liver conditions, pending veterinary approval.
In clinical studies, Solensia has demonstrated a reduction in pain-related behaviours in cats with osteoarthritis. Improvement is often seen after the first dose, with more noticeable benefits typically observed after the second injection. The treatment is designed for long-term use, and effectiveness may increase with regular monthly administration.
Owners may notice a gradual return to more typical behaviours, such as jumping, climbing, or social interaction. These improvements, though individual, can reflect the overall enhancement of the cat’s comfort and wellbeing.
As with any medication, Solensia is not suitable for every cat. It should not be used in cats with known hypersensitivity to frunevetmab or any of the components in the formulation. It is also not recommended for use in pregnant or lactating cats, or in those intended for breeding. Side effects are generally uncommon but may include injection site reactions, vomiting, or lethargy. All adverse effects should be reported to the administering veterinary practice for evaluation.
Veterinarians may also recommend other supportive measures alongside Solensia, such as weight management, joint supplements, mobility aids, and environmental adjustments to reduce stress on affected joints. A coordinated approach that includes Solensia can help address the multifaceted needs of a cat living with osteoarthritis.
By targeting NGF directly, Solensia represents a significant advancement in veterinary pain management. It is a veterinary-administered treatment, ensuring accurate dosing and regular monitoring, which are crucial for safe and effective long-term use.
Solensia is suitable for most adult cats diagnosed with osteoarthritis. Its once-monthly injectable format provides consistent pain relief with minimal impact on the daily routine of both pet and owner.
